As France's leading biocluster, Genopole is an incubator for cutting-edge projects in biotechnology. Located in the city of Évry, just south of Paris, Genopole provides a unique environment for scientists and entrepreneurs seeking to advance research and innovation.

Discover >


Genopole accompanies researchers, postdocs and start-up entrepreneurs through all the phases of their projects to ensure the best possible conditions for business development.

Discover >

Genopole’s citizens

Every day, at Genopole, researchers, entrepreneurs and students cross paths, share ideas and unite forces in a veritable melting pot for innovation.

Discover >


Giving wings to research and empowering employment in our community are cornerstones of Genopole's mission. Catch up on recent scientific advances, the accomplishments of our biotech actors and the events that enliven the biocluster.

Discover >

Innovate with us

Discover >

Galaxy-SynBioCAD: accelerating the arrival of green chemistry

Created by Genoscope’s Genomics Metabolics Unit (at Genopole) and the Micalis Institute, the web portal Galaxy-SynBioCAD is a first-ever “toolshed” for synthetic biology, metabolic engineering and industrial biotechnology. Integrated within the workflow platform Galaxy, the portal enables the design of metabolic pathways in microorganisms for the biological production of compounds conventionally produced via chemistry.
Galaxy-SynBioCAD: accelerating the arrival of green chemistry Galaxy-SynBioCAD: accelerating the arrival of green chemistry

On Wednesday, 26 November, Joan Hérisson, BioRetroSynth research engineer within the Genomics Metabolics Unit (CEA/CNRS/University of Evry Paris-Saclay), presented the Galaxy-SynBioCAD synthetic biology portal, at the International Workshop on Bio-Design Automation (IWBDA), held in Paris in parallel with the renowned international synthetic biology competition iGEM.

Widening the scope of bioproduction

Increasing the number of compounds able to be produced via biological pathways is a major issue for the transformation of synthetic chemistry into a more sustainable bioindustry. But, is it possible to construct a metabolic pathway for any given compound of interest? Can a microorganism by programmed to synthesize it?
Conceived by J.-L. Faulon’s team (Institut MICALIS, INRAE)), which benefits from the presence of several Genopole bioinformaticians, the online portal Galaxy-SynBioCAD can answer those questions.

By uniting a range of synthetic biology tools, guaranteeing their compatibility with the use of standardized languages such as SBML and SBOL, and tying them all together in the workflow platform Galaxy, Galaxy-SynBioCAD is able to:

  1. carry out the complete process of design and engineering for metabolic pathways;
  2. ascertain what enzymes are needed for a given metabolic pathway;
  3. determine the assembly of DNA sequences (coding for the enzymes);
  4. and generate handler scripts for the assembly of plasmids and the production of compounds of interest.

Galaxy-SynBioCAD: all design and engineering steps in just a few clicks

In concrete terms, Galaxy-SynBioCAD delivers a plasmid containing the genes that code for an enzyme able to catalyze the biochemical reactions needed to synthesize a compound of interest. To validate their tool, the authors made it available to other teams and tested it on literature and expert-validated metabolic pathways.

For example, deploying the tool at four different locations, they demonstrated reproducibility by constructing a collection of Escherichia coli strains producing lycopene, an easily identified red pigment. Furthermore, the team benchmarked the tool against 60 molecules previously described in the literature, reporting that in 83% of cases, the literature or expert selected pathways were found in the first 10 pathways generated by Galaxy-SynBioCAD for a same targeted compound in a same bacterial chassis. To classify the validity of synthesis pathways proposed by Galaxy-SynBioCAD, the authors developed a machine learning scoring process trained on a database of nearly 8000 metabolic pathways.

An article published in Nature Communications on 29 August 2022 presented the open-source Galaxy-SynBioCAD portal, for which the Galaxy platform created a new “Synthetic Biology” category specifically.

The work by this Genoscope team in biological engineering, aimed at enabling the bioproduction of a vast range of chemical compounds, contributes to the construction of a bioeconomy sector at Genopole.

Article posted on 28 October 2022


Latest news

©Lionel Antoni - Plateforme d'irradiation expérimentale du LRGK - Plateforme génopolitaine mutualisée avec les acteurs de la communauté scientifique francilienne

The Experimental Irradiation Platform to serve the Île-de-France scientific community

Genopole is making available to the Île-de-France scientific community an Experimental Irradiation Platform equipped with a state of the art generator

Laina Freyer directrice scientifique, Felome

Felome Launches the Commercialization of Genetic Analyses for Companion Cats

Felome will begin the commercialization of a service offering genetic analyses for companion cats, to reveal their predispositions to over 50 diseases, identify their main physical traits, and their similarities with 14 types of breeds.

Lauréats de la promo 3 du programme Gene.iO - Genopole

Three Gene.iO whiz kids rewarded for their innovations

Three Gene.iO whiz kids, Alga Biologics, Fungu'it and Alt Biotech, rewarded for their innovations. Alga Biologics was among the 35 start-ups included in the French Blue Tech Index. Fungu'it and Alt Biotech, were selected to participate in 212 Founders, a start-up accompaniment and financing program by CDG Invest.

l'équipe iGEM 2023 Evry Paris-Saclay - Médaille d'or et p

A prize and gold for the 2023 Évry Paris-Saclay iGEM team

The international synthetic biology competition iGEM celebrated its 20th anniversary. From across the globe, the event drew more than 7,000 students in 400 teams from 66 countries. Genopole was there, among other actors in synthetic biology, to present the biocluster's advantages at its stand, and support the 17 students of the Évry Paris-Saclay team and their outstanding project, OptoGenEYEsis.

Genopole en mission exploratoire au Japon et en Corée du sud - octobre 2023

An exploratory mission to Japan and South Korea for Genopole

Genopole sent a team to Japan and South Korea to present itself and several of its accompanied businesses to major pharmaceutical corporations, investors and Asian bioclusters curious about biotechnological innovations and open to international partnerships.

Ibisc - Genopole's Laboratory

IBISC – Structure prediction for RNA complexes

passes a milestone in structure prediction for RNA complexes, key players in cell biology.

IBISC: A first predictive tool for the emerging field of bifunctional RNA

IBISC: A first predictive tool for the emerging field of bifunctional RNA

The IBISC laboratory has developed IRSOM2, an unprecedented bioinformatics tool for the prediction of bifunctional RNA, a relatively recently discovered class of RNA showing both an ability to code for proteins and an ability to perform biological roles.

Integrating informatics, structural biology and in vivo exploration for the discovery of new medicines

SABNP & Synsight: discovery of new medicines

SABNP and Synsight have validated an integrated, drug discovery approach uniting informatics, structural biology and in vivo exploration.

Alexis Biton and Paul Carouen - Genopole - visiting the Research Triangle Park (USA) accompanied by 3 Genopole's companies

Genopole strengthens its ties with the Research Triangle Park

From Monday March 20 to Thursday March 24, Genopole's Partnership & Business Development team visited the Research Triangle Park biopark in North Carolina to strengthen scientific and industrial collaborations.

Lambe - Genopole's laboratory

Lambe: Detecting coagulation biomarkers with a natural nanopore

The Lambe laboratory showed proof of concept for a coagulation biomarker detection technology based on a natural nanopore.

Andrew Tolonen's team within the unit of Genomics Metabolics (Genoscope - CEA)

Genoscope: Biomanufacturing with bacteria

A team led by Andrew Tolonen has developed a method to optimize the genetic engineering of Clostridium genus bacteria for biotech applications

l’équipe « Dystrophies musculaires progressives » du laboratoire Généthon

Shining light on a key mechanism of Duchenne muscular dystrophy

A Genethon team has provided new insights on a complex genetic mechanism involved in mitochondrial dysfunction in Duchenne muscular dystrophy.

A trio of genome sites associated with arterial hypertension

A trio of genome sites associated with arterial hypertension

Researchers from the CNRGH and PARCC have identified three loci associated with an increased risk of developing primary hyperaldosteronism, a leading cause of arterial hypertension.

Genoscope - CNS - Genopole's laboratory

The story of the domestic donkey told by its genome

Genoscope participated in the sequencing of the DNA of 250 donkeys in a study revealing the domestication of this species highly contributive to human activities to this day.

Equipe Sysfate de l'UMR 8030 - projet T-Fitness

T-FITNESS: Toward empowering CAR-T therapies for solid tumors

The Genopole team SysFate is participating in the international project T-FITNESS. The project, selected by the European Innovation Council, aims to resolve the difficulty of T-cell exhaustion in CAR-T therapies for solid tumors.

Ynsect & Genoscope : Vers la sélection génomique des insectes d’élevage

Toward the genomic selection of farmed insects

France is historically a land of livestock farming. Cows for meat or milk, sheep, pigs, fowl of all sorts; France rears them all. And insects! With its genomic selection project for Tenebrio molitor beetles, the Genopole company Ÿnsect and its biocluster partner, the sequencing center Genoscope, are making France a pioneer in insect farming.

Couverture de la revue Cell Genomics - Le plancton

A feat in the study of planktonic life

A Genoscope research team was part of a pioneering study in environmental genomics. The researchers were able to at least partially reconstitute the genomes of close to 700 eukaryote species.

Logos Istem & Généthon

A two-drug combination to treat limb-girdle muscular dystrophies and cystic fibrosis

The I-Stem and Genethon laboratories have identified a promising drug combination in the setting of three genetic diseases sharing similar molecular mechanisms.

IBISC - IA qui diagnostique et explique grâce à un réseau de neurones

An artificial intelligence to diagnose and explain

The IBISC laboratory has conceived an architecturally-innovative neural network able to provide not only a diagnostic prediction but also a biological explanation.

Christophe Lanneau - Research & Platforms Department Director

News from the human genome

The 1 April edition of Science announced the publication of the human genome with the previously-missing 8% now added to it. Comments from the Genopole Director of Research.

View all >
With the support from
Région île de France